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Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for
patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because
of new treatments and new understandings of breast cancer, however, recommendations published in 2006
regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of
representatives of a number of breast cancer clinical research groups was convened in September 2006 to
update these recommendations. As part of this effort, data published to date were critically reviewed and
indications for neoadjuvant treatment were newly defined.
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introduction
Neoadjuvant systemic therapy (NST) has become a frequently
used option for systemic therapy in primary operable
breast cancer. The quintessence of the last meeting is that all
patients with a clear indication for adjuvant cytotoxic treatment
can be offered chemotherapy preoperatively. These
recommendations focus on early response to NST and on
tailoring therapy to response and biological and histological
markers. A chapter dealing with radiotherapy has been added.
As before [1], the manuscript refers to operable breast cancer
only but recent results demonstrate that patients with locally
advanced disease have comparable benefits from the same
neoadjuvant treatment [2].
methods
In September 2006, an international panel of representatives of a number
of breast cancer clinical research groups was convened for a third
biannual meeting in Biedenkopf, Germany. The panel members
comprised experts in the areas of medical oncology, breast surgery,
breast diagnostics, pathology, radiodiagnostics, and radiation oncology .
Available data from all prospective clinical trials of NST in patients with
operable breast cancer, including abstracts published in the proceedings
of meetings of ASCO (American Society of Clinical Oncology), SABCS
(San Antonio Breast Cancer Symposium), ECCO (European Conference
of Clinical Oncology), ESMO (European Society of Medical Oncology),
and EBCC (European Breast Cancer Conference), were critically
reviewed the objectives of updating the recommendations published in
2006.
recommendations
aims of primary systemic treatment
Three main goals for NST in operable breast cancer were
defined:
 to reduce mortality from breast cancer with reduced toxicity;
 to improve surgical options;
 to acquire early information on response and biology of the
disease.
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Response to neoadjuvant chemotherapy is used in clinical
research as an intermediate endpoint for breast cancer
recurrence and survival.
candidates for NST
As stated in the earlier recommendations a meta-analysis of the
published results showed no difference between neoadjuvant
therapy and adjuvant therapy in terms of survival and overall
disease progression. The individual patient data from these
trials are currently being analysed by the Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG). Therefore,
neoadjuvant treatment can be offered as a standard treatment
and as an alternative to adjuvant treatment to all patients who
are expected to be candidates for adjuvant systemic
chemotherapy.
in which patients is NST with cytotoxic agents the preferred
treatment?
1 Breast conserving surgery (BCS) is not possible or is likely to
be suboptimal in terms of cosmesis.
2 Patients whose tumors express markers of good response to
chemotherapy (low or absent hormone-receptor status,
high-grade, non-lobular invasive histology, high Ki67,
luminal B) should be considered for NST.
in which patients is NST with endocrine agents the preferred
treatment? Endocrine NST alone would be appropriate
mainly for patients in whom BCS is not possible or likely to
be suboptimal in terms of cosmesis and who are not candidates
for neoadjuvant or adjuvant cytotoxic chemotherapy and
in whom predictive markers for endocrine responsiveness
or chemotherapy unresponsiveness are present (estrogen
receptor (ER) and progesterone receptor (PgR) positive, low
grade, invasive lobular histology, low Ki67).
appropriate type of NST
Anthracycline- and taxane-based therapies are widely
used. Capecitabine and Gemcitabine have been recently
incorporated into trials assessing neoadjuvant
chemotherapy (Table 1) [3–5]. Most trials are still ongoing.
Table 1. Current running and closed but unpublished neoadjuvant trials
Author/Trial No. of patients Regimen 1 Regimen 2 Regimen 3 Aim
ABCSG-24 460 EDX ED pCR 16 vs. 27%
ABCSG-24H EDXH EDH pCR
EORTC (Lapatax), phase I 84 FECx3-Dx3+L FECxe-Dx3+H 50%pCR in the 2nd regimen
EORTC (pre-ALTTO) 250 L 3weeks H 3xwekly H+L 3w Change in apoptotic and EGFR pathway
EORTC 1860 No taxane Taxane PFS stratified by p53
EORTC II 490 AP-CMX AP-CMF
French 200 CEX-D FEC-D
German Breast Group
(Geparquattro)
1510 AC-D (+H) AC-DX (+H) AC-D-X (+H) To evaluate the X and the duration
of the treatment. To evaluate H
in Her-2 positive tumors
German Breast Group
(Geparquinto I)
1300 EC-DX ECB-DXB pCR with or without B
German Breast Group
(Geparquinto II)
540 EC-Pw EC-PwRad001 Comparing the pCR in patients not
responding to initial four cycles
of EC
German Breast Group
(Geparquinto III)
600 ECH-DXH ECL-DXL pCR with H compared to L
Korean 200 XD AC
MDACC 930 XD-FEC P-FEC
Neo-ALTTO 450 L+P H+P H+L+P
NSABP (NSABP-B40) 2000 D-AC+/-B DX-AC+/-B DG-AC+/-B Adding capecitabine or gemcitabine
to docetaxel followed by AC,
with or without bevacizumab,
will increase the breast pCR
rates addition of bevacizumab to
3 docetaxel/anthracycline-based
regimens will increase breast pCR
rates
REMAGUS 02 340 ECx4-Dx4 ECx4-Dx4+H ECx4-Dx4+ celecoxib pCR
H randomized in HER2+
Coxib in HER2-
Royal Marsden (POETIC) Periop AI
UK (Neo-TANGO) 800 P (dd)-EC EC-P (dd) GP (dd)-EC
A, doxorubicin; E, epirubicin; P, paclitaxel; D, docetaxel; V, vincristine; F, 5-fluorouracil; C, cyclophosphamide; G, gemcitabine; N, vinorelbine;
M, methotrexate; X, capecitabine; B, bevacizumab; H, trastuzumab; L, lapatinib; Rad 001, everolimus; AI, aromatase inhibitor; w, weekly; dd, dose-dense.
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Combined or sequential use of anthracyclines and taxanes are
both acceptable.
Trastuzumab should be incorporated into the regimen in
patients with Her-2/neu positive disease, but concomitant use
with an anthracycline (preferably one with lower cardiac
toxicity, e.g. epirubicin/pegylated doxorubicin) should only
occur in clinical trials. The concomitant application of
trastuzumab and epirubicin seems safe as demonstrated in
the Geparquattro trial of the German Breast Group and the
MD-Anderson trial [6].
There are limited data on the use of preoperative endocrine
treatment in premenopausal patients. A combination of
Gonadotropin Releasing Hormone analogue (GnRH) and
letrozole in premenopausal patients with ER and PgR ‡ 10%
with a median duration of 5 and 4 months, respectively,
demonstrated a pCR of 3% and a rate of breast conservation
of 42% [7]. A tailored approach of chemoendocrine therapy
with or without an AI demonstrated pCR rates of 7% and 11%,
respectively, and BCS rates of 62% and 58%, respectively [8].
However, none of the approaches can be used as a routine
therapy. As has been stated before, chemotherapy and
tamoxifen should be delivered sequentially but no such data
exist for ovarian function suppression (OFS). Hence, the
concomitant use of any indicated chemotherapy with GnRH
might be considered as acceptable in women with a desire of
pregnancy [9]. A combined chemoendocrine approach,
including an aromatase inhibitors (AI), is investigational.
The AIs are well-established in the neoadjuvant endocrine
treatment of postmenopausal women with hormone-responsive
tumors 1. The IMPACT trial could not demonstrate a
significant benefit in terms of the clinical response rate for
the AIs over tamoxifen [10].
appropriate duration of NST
It has been accepted that the chemotherapy should be
completed before surgery, except for the rare patient in whom
disease progression during treatment threatens to make the
patient inoperable. At least six cycles should be administered
over 4 to 6 months. Endocrine treatment should be given for
4 to 6 months before proceeding to surgery [11].
early response evaluation
To avoid unnecessary toxicity without potential for benefit
from the treatment, early response evaluation should be
performed. The time of response evaluation depends on the
treatment given and should be performed 6–9 weeks after the
start of treatment.
Patients with an early clinical response seem to derive the
most benefit from a non cross-resistant regimen. In patients
with insufficient early response, especially progressive disease,
a switch of treatment should be considered. The aim in those
patients is to spare toxicity because they gain little, if any,
benefit from a non cross-resistant regimen.
predictors of response or resistance
Predicting the chance of response to treatment before
starting NST is an important research goal. Patients with a low
chance of a pCR, and especially a low chance of a clinically
useful response, might then be spared unnecessary toxicity [12].
Patients whose tumors express markers predictive of
chemo-response are the best candidates for neoadjuvant
chemotherapy. Negative hormone receptor status is one of
the strongest predictive markers for chemo-response in general.
Tumors completely lacking such receptors were found to be
particularly sensitive to preoperative cytotoxic agents, but
despite a pathological complete remission rate exceeding 40%,
survival of patients with this phenotype was reported in several
studies to be shorter than for those with receptor-positive
tumors [13–15 ].
Several neoadjuvant trials demonstrate a difference between
lobular invasive and ductal invasive carcinomas in terms of
response to NST and BCS [16–18]. However, there is still
a debate as to whether the lower response rate of lobular
cancers to NST translates into a worse overall survival.
Recently, investigations have concentrated on predicting
response to specific therapies based on various biological
markers. Her-2/neu was one of the most intensively studied
ones. So far there is no clear evidence that Her-2/neu
positive breast cancers repond better than negative ones to
anthracycline- and taxane-based chemotherapy [19–20].
Her-2/neu negative breast cancer patients might respond
better to a taxane than to an anthracycline treatment [21].
Topoisomerase IIa has been demonstrated to be an
independent predictor of clinical tumor response, especially
to anthracycline, but in a gene array, analysis failed to predict
pCR [22, 23]. It is unlikely that a single biologic marker will
ever be able to differentiate definitively between responders
and non-responders [24].
An alternative to measuring one specific marker is to use
a combination of different markers and/or the establishment of
a specific gene-expression profile that can predict response to
neoadjuvant therapy. Gene-expression profiling has become
quite popular, but has so far failed to identify a definitive
population that should be spared chemotherapy, nor has this
approach identified a population that has more than an 80%
chance of a pCR (Table 2).
It is well known that patients with a pCR have a better
overall survival than those who did not achieve a pCR. Data
are limited regarding the prognostic significance of residual
in situ ductal cancer (DCIS) [25, 26]. Apart from the pCR
in the breast, one of the most important prognostic factors
after neoadjuvant therapy is the post-treatment lymph node
status [27].
Chemosensitivity testing is investigational and should not be
used outside clinical trials.
imaging. Imaging is an important adjunct to neoadjuvant
therapy. Before starting therapy, it helps to identify the extent
of the disease; during therapy it can be used to evaluate
reponse; and after NST, it may assist with evaluation of the
extent of residual tumor and to guide surgery. It will be
important to identify accurate methods for measuring early
treatment response in order to maximize treatment effect and
minimize treatment toxicity without benefit.
Clinical examination based on palpable change in tumor
size is the most common method for monitoring treatment
effect. However, it seems advisable to perform ultrasound
and clinical examination in combination with mammography
Annals of Oncology review
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for response evaluation to rule out over as well as
under-estimation of response [28]. In case of ambiguous
results, multicentricity, and lobular invasive cancers,
a quantitative contrast-enhanced Magnetic Resonance Imaging
(MRI) might be helpful [29] (Table 3). Some studies have
shown MRI to be superior to mammography, ultrasound, and
clinical examination in evaluating the extent of the tumor [30].
The agreement of pathologic residual tumor size with
mammography or sonography residual tumor is moderate,
especially in lobular invasive cancers [31, 32]. Investigations
suggest that findings on MRI strongly correlate with the
pathological response [33]. At the time of surgery, MRI may
therefore help to identify residual disease more accurately.
Studies in the neoadjuvant setting demonstrate that [F-18]
Fluorodeoxyglucose Positron Emisson Tomography (FDG
PET) might predict pathologic response at 2 to 3 months
after the start of chemotherapy [34–36]. Combining FDG
PET and MRI for response evaluation was shown to be
complementary [37]. However, changes in imaging generally
manifest themselves later than changes in underlying tumor
function, e.g vascular density and permeability [38]. Newer
techniques, such as proton magnetic resonance spectroscopy,
diffusion weighted imaging [39], interstitial fluid pressure [40]
and Doppler ultrasound are under investigation.
local treatment: surgical issues and radiotherapy
surgical management of the breast. Breast surgery after
primary chemotherapy should be performed according to
the guidelines for breast surgery without prior systemic
therapy. Breast-conservation techniques include lumpectomy,
wide excision, and quadrantectomy [41]. For medium and
large breasts, dermoglandular flaps can be used to fill the
excision site. If intramammary glandular flaps are used or if
reduction mammoplasty techniques are used, the initial
tumor location should be marked by clips to allow planning
of subsequent breast irradiation [42].
If mastectomy is indicated, postoperative radiotherapy is
also indicated in most of these patients, and therefore breast
reconstruction should usually be delayed until 6–12 months
after completion of breast irradiation.
Data on breast conservation after neoadjuvant chemotherapy
is limited, but several studies have demonstrated that NST
can increase the feasibility of breast conservation without
adversely affecting survival. There are some factors that might
influence the success of BCS, such as tumor size, lymphatic
invasion, nodal status, or diffuse microcalcifications [43, 44].
Also, some data suggest that converting young patients
who were not candidates for breast conservation to
lumpectomy candidates with NST may be associated with
Table 2. Gene expression profiles for predicting pCR
Author n Objective PST Genes Accuracy % (95%CI) PPV/NPV % N
Ayers et al. (2004) [64] 42 ypT0/is PAC-FAC 74 85 (52–94) 100/73 18
Hannemann et al. (2005) [65] 48 ypT0/is AC/AD
Thuerigen et al. (2006) [66] 100 ypT0/is GE-D GEDoc 512 88 (75–95) 64/95 48
Hess et al. (2006) [67] 133 ypT0/is ypN0 PAC–FAC 26 76 (62–87) 52/92 51
Rody et al. (2005) [68] 50 ypT0 TAC 70
Chang et al. (2003) [69] 24 cRR D 92 100
Iwao-Koizumi et al. (2005) [70] 44 cRR D 85 80 73
Cleator (2006) [71] 40 cRR AC 293 67
Gianni et al. (2005) [72] 86 pCR AP-P Ass Sign association
A, doxorubicin; E, epirubicin; P, paclitaxel; D, docetaxel; F, 5-fluorouracil; C, cyclophosphamide; G, gemcitabine;
PPV, positive predicate value; NPV, negative predictive value.
Table 3. Predicition of pathological response by clinical evaluation
Author n Correlation coefficient with pathological tumor size with presurgical tumors size
Physical examination Mammography Sonography MRI Others
Forouhi et al. (1994) [56] 35 0.88 0.96 0.94 – –
Gawne-Caine (1995) [57] 16 0.74 0.85 0.61
Herrada et al. (1997) [58] 100 0.73 0.6 0.65
Akashi-Tanaka et al. (2001) [59] 57 0.57 0.56 0.55
Fiorentino et al. (2001) [60] 141 0.68 0.29 0.33
Bodini et al. (2004) [61] 73 0.58 0.72
Chagpar et al. (2006) [32] 189 0.42 0.42 0.41
Peintinger et al. (2006) [31] 162 0.66
Belli et al. (2006) [62] 45 0.97
Akazawa et al (2006) [63] 38 0.55 0.48 0.90
MRI, Magnetic Resonance Imaging.
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a higher risk of local recurrence. However, this does not
appear to compromise patient overall outcomes.
Surgical planning and execution should take into account the
size of the original tumor and the response to NST [45].
surgical management of the axilla. The standard surgical
procedure for staging the axilla has been axillary dissection,
aiming at removal of at least 10 axillary lymph nodes.
Sentinel lymph node biopsy (SLN) before the start of NST is
an option that has been advocated by some. The accuracy of
SLN biopsy for determining lymph-node status before primary
surgery has been confirmed in a metaanalysis with pooled
data from 69 trials with more than 8000 patients [46]: 30%
of patients with T1 tumours had involved lymph nodes.
SLN biopsy after NST is an acceptable approach in patients
with clinically tumor-free axillary lymph nodes after NST.
It may be performed with accuracy that is comparable to that
in primary surgery patients [47]. The identification rate
(pooled estimate 90%) and the false-negative rate (pooled
estimate 12%) for SLN biopsy reported in a recent
meta-analysis were similar for patients with and without
preoperative chemotherapy [48]. The SLN biopsy procedure
and histologic examination should be performed according to
the consensus recommendations [49, 50]. However, this
procedure is still controversial after neoadjuvant chemotherapy
and should therefore be used with caution in patients
presenting with grossly positive nodes, and only in patients
with a clinically negative axilla after chemotherapy Patients
should be informed by the surgeon that this approach is
unproven. Intraoperative frozen sections of the SLN should
be performed. In the subsequent paraffin histology, step
sections, as well as immunohistochemical staining for
epithelial markers such as cytokeratins, should be perfomed.
If the frozen section and the definitive histology show no
tumor cells in the SLN, axillary dissection is not needed and
the axilla can be considered tumor-free. If SLN mapping fails
or if the SLN is positive for metastases (> 0.2mm), then
standard axillary dissection should be carried out.
We cannot yet identify any patients with certainty who might
forego excision of the primary tumor site. Whether we could
spare the patient the operation on the axilla has not been
systemtically investigated in those patients who respond well to
NST and have a clinically negative axilla
radiotherapy. It has been proven that systemic treatment and
radiotherapy are independent factors influencing the outcome
of patients with operable breast cancer [51]. However, the
addition of preoperative radiotherapy to NST in patients with
operable tumors has not yet been adequately proven to be
effective. Limited data demonstrate additional benefits in terms
of higher rates of pCR and BCS, especially in T3 and T4
tumors. Regardless, since up to one-third of patients with
clinical complete remission after NST still have pathologic
evidence of residual tumor in the breast, radiotherapy alone
cannot replace adequate surgery [52].
It appears that postmastectomy radiation therapy is
beneficial in patients with an initial T3 or T4 tumors, even in
those who subsequently achieved a pCR, because the rate of
locoregional recurrence remains high in these patients [53].
Postmastecomy radiotherapy is not justified in patients with
T1 or T2 disease and one to three involved lymph nodes
because of the low 5-year risk of local regional recurrence in
these patients [54]. However, since the number of involved
lymph nodes can be altered by NST, postmastectomy
radiotherapy should also be considered in patients who present
initially with clinically positive lymph nodes.
potential risk for local recurrence
Some patients will not be good candidates for breast
conservation after NST, regardless of response. For example,
women with pathologically proven multi-centric disease,
should generally undergo mastectomy. It is not clear that they
will benefit from NST outside of a clinical trial, unless they
present with locally advanced or inoperable disease. Younger
patients (< 40) who undergo breast-conserving treatment that
was not possible without NST may have a higher local
recurrence rate than other patients, but this does not necessarily
compromise patient survival, and may reflect the biology of
breast cancer in this population more than the choice of
treatment. Since these women are often the most emphatic in
desiring breast conservation, age should not be
a contraindication to using NST to achieve this goal.
Figure 1. Standardized histopathological approach to the assessment of
breast cancer specimen from neo-adjuvant chemotherapy.
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The Early Breast Cancer Trialists’ Collaborative Group
demonstrated in the 2006 meta-analysis a slightly increased
risk for local recurrence (by absolute 3%) for patients with
neoadjuvant therapy. However, the analysis includes some old
trials with less efficient chemotherapy regimens, which are not
used any longer. Reports from single institutions and more
modern treatment could not demonstrate a negative effect.
Another meta-analysis on this issue suggested that higher local
recurrence rates after NST are mostly the result of trials that
allowed RT alone without surgery after NST [55]. The risk of
local recurrence may be optimized by efficient communication
between surgeons and pathologists.
standardized pathology approach
Before starting any NST, a core biopsy should be performed
to confirm the diagnosis of invasive cancer and to obtain
predictive markers such as histological subtype, tumor
grading according to Elston and Ellis, ER and PgR status and
Her-2/neu status.
The surgical specimen should be examined in a standardized
approach (Figure 1). The pathologist should determine the size
of residual tumor (invasive and non-invasive separately),
the tumor free margins in all six directions of the specimen, the
regression score (using one of the national or international
scoring systems) and repeat the ER, PgR, and Her-2/neu
assessments at least for initially negative disease. For nodal
status the pathology report should give the total number of
nodes, the number of positive nodes with information on the
size of the metastatic foci and regressive changes, as well as the
number of nodes with therapy-induced regressive changes,
but without residual tumor cells. All tumor parameters
should be reported according to the TNM system with the
addition of ‘‘y’’ to indicate the status post therapy.
Conversely, the pathologist needs to be given clinical
information (Table 4) for optimization of the histopathological
work up. Quality control can be assured by spot-checking
and monitoring of pathology reports.
conclusion and recommendations
For patients to be treated with NST chemotherapy, at least six
cycles of an anthracycline- and taxane-containing regimen
should be planned and given preoperatively over 4–6 months.
Trastuzumab should be included in the regimen for
patients with Her-2 positive tumors The concurrent use of
Trastuzumab with an anthracycline containing regimen
should only be given in clinical trials.
LHRH analogues in premenopausal patients are
investigational.
Primary endocrine therapy with aromatase inhibitors (AIs)
should be offered to women if the tumor is expected to be
highly endocrine responsive.
Concepts for clinical trials related to NST:
 large adjuvant trials should be preceded by adequately
powered randomized neoadjuvant trials to support the
validity of the scientific question and the statistical design;
 role of RT in pCR patients (need and schedule);
 RT and surgery trials need to be funded.
Outside clinical trials:
 patients need to be referred to a breast surgeon and
a radiation oncologist before initiating NST
(multidisciplinary management approach is mandatory);
 to avoid extensive local relapse, close follow-up by
members of all involved disciplines is needed throughout
the course of treatment and after completion of therapy;
 SLN biopsy can be offered to women after neoadjuvant
therapy.
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Table 4. Four essential parameters the surgeon should provide to the pathologist for each tumor resection specimen from neoadjuvant therapy
Clinical information Why is this information important for the pathologist?
1. A neoadjuvant therapy has been performed
(cytotoxic or endocrine).
Different histopathological approaches after neo-adjuvant therapy:
 modified tumor classification (ypTNM) and regression grading have
to be reported;
 histological changes in poor-responders may be very uncharacteristic
and may therefore not be recognized without clinical information.
2. The pretherapeutic tumor size and localization. The histopathological evaluation for complete pathological response
is dependent on the size and localization of the pretherapeutic
tumor bed which cannot necessarily be determined from the
resection specimen itself.
3. Localization of residual tumor foci in clinical
and imaging approaches.
To reduce local recurrences after neoadjuvant therapy, an adequate
sampling of margins is mandatory.
Since residual tumor may be discontinuously located close to the
margins, an exact clinical description of the localization is needed.
4. Clinical response. In the setting of clinical complete response, the macroscopic
evaluation and the sampling will be extended.
Histological workup time will be much shorter if this information
is given when sending the specimen.
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